Business Wire

IL-ADAMS-STREET-PARTNERS

Share
Brijesh Jeevarathnam to Succeed Kelly Meldrum as Global Head of Fund Investments at Adams Street Partners

Adams Street Partners, LLC, a private markets investment firm with more than $50 billion of assets under management, announced today that Brijesh Jeevarathnam will be promoted to Partner & Global Head of Fund Investments. Jeevarathnam, who joined Adams Street as a Partner in Primary Investments in 2016, will also become a member of the firm’s Executive Committee as part of his new role.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005265/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Brijesh Jeevarathnam has been promoted to Partner & Global Head of Fund Investments of Adams Street Partners. (Photo: Business Wire)

Jeevarathnam succeeds Kelly Meldrum, who is retiring after 17 years as a Partner & Head of Primary Investments at the firm. Meldrum will transition her duties at year-end and will make herself available through the end of Q1 2023.

“Over her long tenure with Adams Street, Kelly has made innumerable contributions to the firm, not the least of which was building a terrific team of seasoned partners who make material contributions to our clients’ success,” said Jeff Diehl, Managing Partner & Head of Investments at Adams Street. “I am excited for Brijesh to now take on this larger role and am confident he will build on Kelly’s success after a smooth leadership transition over the next six months.”

Since joining Adams Street, Jeevarathnam has been instrumental in the creation and scaling of the firm’s Venture Innovation and Leaders programs as well as being the portfolio manager on multiple separately managed accounts. Prior to Adams Street, Jeevarathnam spent 10 years at Commonfund Capital where he held a leadership role and helped manage a $14 billion global private capital portfolio.

Also as part of the leadership transition, Saguna Malhotra, currently a Partner in Primary Investments, will be promoted to the role of Partner & Head of Global Buyout Fund Investments. Malhotra will focus on global calibration and strategy for Adams Street’s buyout fund portfolios globally. Malhotra joined the firm in 2015 from Stanford Management Company, where she oversaw a $6 billion global private equity portfolio.

“The entire Adams Street team will miss Kelly both personally and professionally and we wish her all the best in her next chapter,” said Diehl. “For both Brijesh and Saguna, they have earned their well-deserved expanded roles and I look forward to their contributions moving forward.”

About Adams Street Partners

Adams Street Partners is a global private markets investment manager with investments in more than thirty countries across five continents. The firm is 100% employee-owned and has $50 billion in assets under management. Adams Street strives to generate actionable investment insights across market cycles by drawing on 50 years of private markets experience, proprietary intelligence, and trusted relationships. Adams Street has offices in Austin, Beijing, Boston, Chicago, London, Menlo Park, Munich, New York, Seoul, Singapore, and Tokyo. Visit www.adamsstreetpartners.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005265/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

Illumynt Reports Q3 2025 Business Update17.10.2025 14:39:00 CEST | Press release

Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye